Department of Surgery
Michael Shapiro, MD, B.A.
Clinical InfoMedical Expertise
General Surgery, Kidney and Pancreas Transplantation. Particular interest in patients with renal failure, immunosuppression or surgical infections, thyroid, parathyroid and benign pancreas surgery.
University Hospital, Newark
Hackensack University Medical Center
St. Mary's Hospital - Passaic
Insurance Participation: with Provider Number ( where applicable ) The information below is subject to change and should not be relied upon until after it is verified with the insurance company. In addition, psychiatric providers should be contacted directly for information on their participation with managed care and insurance companies.
Dr. Shapiro is a Harvard-trained General Surgeon with over 30 years of expertise in Kidney and Pancreas transplantation, and the surgery of patients with renal failure and diabetes. He has a research background in cellular and viral immunology, having studied under Nobel laureate Dr. Baruj Benacerraf. His is former Chief of organ transplantation at Boston's Beth Israel Hospital, and at Hackensack University Medical Center. He moved to Rutgers - New Jersey Medical School in 2013 to become Surgical Residency Program Director. He also has extensive experience in clinical and transplant bioethics, and currently Chairs the University Hospital Bioethics Committee.
MD, 1977, University of Rochester School of Medicine and Dentistry, Medicine
B.A., 1973, Williams College, Chemistry
Licensure & Certification
|Shapiro, M.E., Age should be considered in the allocation of deceased donor kidneys. Seminars in Dialysis, 2012, 25:682-685. PMID 23173894|
|Danovitch, G.M., Shapiro, M.E., Lavee, J. The use of executed prisoners as a source of organ transplants in China must stop. AJT, 2011, 11:426-428. PMID 21342444|
|Shapiro, M.E. and Ward, F.R., The Problem with DCDD is the Dead Donor Rule, American Journal of Bioethics, 2015,15: 15-16. PMID 26225506|
|Shapiro, M.E., “The development of new allocation policy for deceased donor kidneys.” Curr Opin Nephrol, Hypertens., 2007, 16: 512-515.|
|Oliver, J.B., Beidas, A.K., Bongu, A., Shapiro, M.E., A comparison of long-term outcomes of portal versus systemic venous drainage in pancreatic transplantation: a systematic review and meta-analysis, Clinical Transplantation, 2015, PMID 26172035.|
|Strehlau, J., Pavlakis, M., Lipman, M., Shapiro, M., Vasconcellos, L., Harmon, W., Strom, T.B. Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc. Natl. Acad. Sci. USA, 1997; 94:695-700.|
|Shapiro, M.E., and Liu, M. Prolongation of Islet Allograft survival by Anti-CD45 Antibody Pretreatment. Transplant Proc., 1995; 27:613-14.|
|Elahi, D., Clark, B.A., McAloon-Dyke, M., Wong, G., Brown, R., Shapiro, M.E., Minaker, K., Flanagan, K., Pruett, T., Gingerich, R., Hanks, J., and Anderson, D.K. Islet cell responses to glucose in human transplanted pancreas. Am J. Physiol., 1991; 261: E800-E808.|
|Shapiro, M.E., Burakoff, S., Benacerraf, B., and Finberg, R.W. “IR Gene Control of the Cytotoxic T Lymphocyte Response to Sendai Virus: H-2k Mice are Low responders to Sendai”. J. Immunol. 1981; 127:2571.|
|Shapiro, M.E., Onderdonk A.B. Kasper, D.L. and Finberg, R.W. “Cellular Immunity to Bacteroids fragilis Capsular Polysaccharide”. J. Exp. Med. 1982; 155:1188.|